LY-3885125

N/A

Report date: 2026/05/11 20:01:57

Base Information

Drug NameLY-3885125
Drug Alias NameLY3885125LY-3885125
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionSREBP cleavage activating protein inhibitors
TargetsSREBP cleavage activating protein
Therapy Area/IndicationsDyslipidemiasMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEli Lilly And Company
Active IndicationsN/A
Inactive IndicationsDyslipidemiasMetabolic Dysfunction-Associated Steatotic Liver Disease

Other Information

ATC CodeN/A
Related LinksN/A